Hengrui Pharma has provided an update on its progress regarding the repurchase of its A-shares.

During the month of June 2026, the company repurchased 1.414 million shares through the Shanghai Stock Exchange trading system using the centralized competitive bidding method. These repurchased shares represent approximately 0.021% of the company's total share capital. The highest price paid per share was RMB 47.70, while the lowest price was RMB 45.30. The total amount paid for these repurchases, excluding transaction fees, reached RMB 66.0151 million.

As of June 30, 2026, the cumulative number of shares repurchased under this buyback program has reached 13.4702 million. These shares, also acquired via the Shanghai Stock Exchange's centralized bidding system, account for about 0.20% of the company's total issued share capital. The highest price paid in the program to date is RMB 70.00 per share, and the lowest price remains RMB 45.30 per share. The total expenditure for the cumulative repurchases, excluding transaction costs, amounts to RMB 837.996 million.